Drug intelligence / Profile preview

3SC009

Development stage: Phase 1
Lead developer: 3SBio
Administration: Parenteral

Overview

3SC009 is an investigational biologic drug being developed by Shenyang Sunshine Pharmaceutical (a subsidiary of 3SBio) for the treatment of advanced solid tumors. In 2026, a Phase 1 clinical trial (CTR20263273) was initiated in China to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of 3SC009 for injection in adults with unresectable advanced or metastatic solid tumors. The specific target, mechanism of action, and molecular modality of 3SC009 remain undisclosed by the developer.

Other names: 注射用3SC009

Beyond the preview

Go deeper on 3SC009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3SC009.